Proteomics of Apoptosis of Multiple Myeloma Cells Induced by Proteasome Inhibitor PS-341.

Haitao Jia,Feng Ge,Xinpeng Lu,Huilan Zeng,Liping Li,Zhipeng Chen,Chunhua Lu

DOI: https://doi.org/10.3969/j.issn.1672-7347.2010.08.003

2010-01-01

Abstract:OBJECTIVETo compare the proteome difference between multiple myeloma cell line U266 cells treated and untreated with PS-341, to investigate the potential drug targets, and to provide theoretical evidence for clinical therapy of multiple myeloma.METHODSTwo-dimensional gel electrophoresis (2-DE) was performed to separate proteins from treated and untreated U266 cells with proteasome inhibitor PS-341. ImageMaster 2D Platinum software was used to analyze 2-DE image, and matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) was used to identify the differentially expressed proteins. The expression levels of differential protein BAG-2 in the 2 groups of U266 cells lines were detected by Western blot.RESULTSThe 2-DE reference pattern of treated and untreated U266 cells with PS-341 was established. A total of 31 differential proteins were identified by MALDI-TOF-MS, 27 of which were down-regulated after PS-341 treatment. The differential expression level of BAG-2 in the 2 groups of U266 cells was confirmed by Western blot.CONCLUSIONSome down-regulated proteins may be the potential drug targets of proteasome inhibitor PS-341.